03:44 AM EDT, 05/22/2025 (MT Newswires) -- Sanofi ( SNY ) has agreed to acquire Vigil Neuroscience ( VIGL ) in a cash transaction with an equity value of up to $600 million, the companies said late Wednesday.

Under the terms of the deal, Vigil shareholders will receive an upfront payment of $8 per share in cash plus a non-tradeable right to receive a possible additional $2 per share in cash following the first commercial sale of Alzheimer's therapy VG-3927 if achieved within a specific time period, the companies said.

Sanofi ( SNY ) and Vigil said they expect the transaction to close in Q3.

Iluzanebart, Vigil's monoclonal antibody program, is not part of the Sanofi ( SNY ) deal and will return to Amgen ( AMGN ) , which was the original licensor, the companies said.